Hipertensión arterial y síndrome metabólico

Yusuf, 2004, Effect of potentially modificable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, Lancet, 364, 937, 10.1016/S0140-6736(04)17018-9 Tunstall-Pedoe, 2000, Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations, Lancet, 355, 688, 10.1016/S0140-6736(99)11181-4 González-Juanatey, 2001, Impacto de la hipertensión en la cardiopatía en España. Estudio CARDIOTENS 1999, Rev Esp Cardiol, 54, 139, 10.1016/S0300-8932(01)76284-7 Ramos, 2004, The role of age in cardiovascular risk factor clustering in non-diabetic population free of coronary heart disease, Eur J Epidemiol, 19, 299, 10.1023/B:EJEP.0000024697.55346.c2 Reaven, 2004, The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals, Endocrinol Metab Clin North Am, 33, 283, 10.1016/j.ecl.2004.03.002 Grundy, 2004, Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management, Circulation, 109, 551, 10.1161/01.CIR.0000112379.88385.67 2002, Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and reatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Alberti, 2005, The metabolic syndrome: a new worldwide definition, Lancet, 366, 1059, 10.1016/S0140-6736(05)67402-8 Chobanian, 2003, Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Reaven, 1996, Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system, N Engl J Med, 334, 374, 10.1056/NEJM199602083340607 Alexander, 2003, NECP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older, Diabetes, 52, 1210, 10.2337/diabetes.52.5.1210 Rutter, 2004, C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study, Circulation, 110, 380, 10.1161/01.CIR.0000136581.59584.0E Sattar, 2003, Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study, Circulation, 108, 414, 10.1161/01.CIR.0000080897.52664.94 Ridker, 2003, C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women, Circulation, 107, 391, 10.1161/01.CIR.0000055014.62083.05 Schillaci, 2004, Prognostic value of the metabolic syndrome in essential hypertension, J Am Coll Cardiol, 43, 1817, 10.1016/j.jacc.2003.12.049 Ascaso, 2003, Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population, Eur J Intern Med, 14, 101, 10.1016/S0953-6205(03)00022-0 Cheal, 2004, Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome, Diabetes, 53, 1195, 10.2337/diabetes.53.5.1195 Guallar-Castellón, 2002, Asociación de la enfermedad cardiovascular con el sobrepeso y la obesidad en España, Med Clin (Barc), 118, 616, 10.1016/S0025-7753(02)72470-6 Alegría, 2005, Prevalencia de síndrome metabólico en población laboral española: Registro MESYAS, Rev Esp Cardiol, 58, 797, 10.1157/13077231 Verma, 2003, Resistin promotes endotelial cell activation: further evidence of adipokine-endothelial interaction, Circulation, 108, 736, 10.1161/01.CIR.0000084503.91330.49 Iwashima, 2004, Hypoadiponectinemia is an independent risk factor for hypertension, Hypertension, 43, 1318, 10.1161/01.HYP.0000129281.03801.4b Eikelis, 2003, Interactions between leptin and the human sympathetic nervous system, Hypertension, 41, 1072, 10.1161/01.HYP.0000066289.17754.49 Hall, 2003, The kidney, hypertension and obesity, Hypertension, 41, 625, 10.1161/01.HYP.0000052314.95497.78 Chen, 2004, The metabolic syndrome and chronic kidney disease in U.S. adults, Ann Intern Med, 140, 167, 10.7326/0003-4819-140-3-200402030-00007 Cordero, 2005, Factores de riesgo cardiovascular y syndrome metabólico asociados con la disfunción renal subclínica, Med Clin (Barc), 125, 653, 10.1157/13081374 Scuteri, 2004, Metabolic syndrome amplifies the age-associated increases in vascular thickness and stiffness, Am J Coll Cardiol, 43, 1388, 10.1016/j.jacc.2003.10.061 Verdecchia, 2004, Adverse prognostic significance of new diabetes in treated hypertensive subjects, Hypertension, 43, 963, 10.1161/01.HYP.0000125726.92964.ab Reilly, 2003, The metabolic syndrome: more than the sum of it́s parts?, Circulation, 108, 1546, 10.1161/01.CIR.0000088846.10655.E0 Álvarez, 2003, Prevalencia del síndrome metabólico en la población de la Comunidad Canaria, Med Clin (Barc), 120, 172, 10.1157/13043145 Gimeno, 2004, Influencia del síndrome metabólico en el riesgo cardiovascular de pacientes con diabetes tipo 2, Rev Esp Cardiol, 57, 507, 10.1157/13062916 Wang, 2004, The prevalence of prehypertension and hypertension among US adults according to the new Joint National Committee guidelines: new challenges of the old problem, Arch Intern Med, 164, 2126, 10.1001/archinte.164.19.2126 Greenlund, 2004, Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000, Arch Intern Med, 164, 2113, 10.1001/archinte.164.19.2113 Kanauchi, 2004, Metabolic syndrome and new category “pre-hypertension” in a Japanese population, Curr Med Res Opin, 20, 1365, 10.1185/030079904X2042 Cordero, 2006, Prehypertension is associated with insulin resistance state and not to initial renal function impairment: a MESYAS registry substudy, Am J Hypertens, 19, 189, 10.1016/j.amjhyper.2005.08.018 Cordero, 2006, Prevalencia de síndrome metabólico y asociación con la cardiopatía isquémica en pacientes cardiológicos ambulatorios, Rev Clin Esp, 10.1157/13088584 Orchard, 2005, The Effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial, Ann Intern Med, 142, 611, 10.7326/0003-4819-142-8-200504190-00009 Bautista-Castaño, 2003, Variaciones tras tratamiento de pérdida ponderal, Med Clin (Barc), 121, 485, 10.1157/13053138 Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161 Hillege, 2003, Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial, Eur Heart J, 24, 412, 10.1016/S0195-668X(02)00526-2 Tokmakova, 2004, Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study, Circulation, 110, 3667, 10.1161/01.CIR.0000149806.01354.BF González-Juanatey, 2003, Actualización (2003) de las Guías de Práctica Clínica de la Sociedad Española de Cardiología en hipertensión arterial, Rev Esp Cardiol, 56, 487, 10.1157/13047014 Dahlöf, 2005, Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 Bakris, 2004, Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled study, JAMA, 292, 2227, 10.1001/jama.292.18.2227 Pepine, 2003, A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial, JAMA, 290, 2805, 10.1001/jama.290.21.2805 Després, 2005, Effects of rimonabant on metabolicrisk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Sever, 2004, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 Colhoun, 2004, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial, Lancet, 364, 685, 10.1016/S0140-6736(04)16895-5 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Wang, 2004, Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome, Am J Cardiol, 93, 362, 10.1016/j.amjcard.2003.10.022 Choi, 2004, Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes, Diabetes Care, 27, 2654, 10.2337/diacare.27.11.2654 Dormandy, 2005, Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial, Lancet, 366, 1279, 10.1016/S0140-6736(05)67528-9